Ironwood Pharmaceuticals
Update in progressIRWD (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Ironwood Pharmaceuticals is a Boston-based biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. It markets linaclotide (LINZESS/CONSTELLA) for adults with IBS with constipation or chronic idiopathic constipation and for children with functional constipation. It is developing IW-3300 for visceral pain conditions and Apraglutide for short bowel syndrome and acute GVHD. Partnerships include AbbVie, AstraZeneca, and Astellas. It was formerly Microbia, Inc., incorporated in 1998.
Company score
- Sentiment
- -0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.13
- Governance
- -0.18
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Thomas A. McCourt
- Founded1998
- Employees100
- Websiteironwoodpharma.com
Identifiers
- ISINUS46333X1081
- FIGIBBG000GBZ3J2
- LEI549300PC8MR6QHH6P296
- CUSIP46333X108
- CIK0001446847